文献速递药物不良反应与药物警戒

因不可接受毒性停用医院门诊治疗:患者与治疗登记处回顾性研究

Withdrawal of hospital outpatient treatments in severe diseases due to unacceptable toxicity: A retrospective study from the register of patients and treatments.
PubMed 文献 · Br J Clin Pharmacol · 2020-12-03

该研究基于2014年1月至2017年12月的患者与治疗登记处(RPT),回顾性分析因不可接受毒性而停用医院门诊治疗(HOT)的情况。最常见药物为来那度胺、贝伐珠单抗和舒尼替尼,常见ADR为血细胞减少、腹泻、乏力和神经病变;所有ADR均为严重,仅9例(5例患者)通过自发报告上报。

要点

  • 因不可接受毒性停用HOT占登记处1.5%条目和1.7%患者。
  • 最常见涉及药物为来那度胺、贝伐珠单抗和舒尼替尼。
  • 所有ADR均为严重,仅少数通过自发报告上报。

核心结论

  • 患者与治疗登记处(RPT)可获得关于严重和未知ADR的有价值信息。
  • 此类登记处是补充自发ADR报告的有用工具。

研究设计与样本

  • 回顾性研究,数据来自2014年1月至2017年12月的患者与治疗登记处(RPT)。
  • 识别因不可接受毒性停用HOT的登记,从电子健康记录检索患者人口学与临床特征、ADR及药物治疗信息。
  • 根据西班牙药物警戒系统算法评估因果关系和ADR既往知识。
  • 从欧洲药品管理局(EMA)获取HOT风险管理计划(RMP)及倒置黑三角药品分类信息。

主要发现

  • 136条登记(1.5%)对应135例患者(1.7%)因不可接受毒性停用HOT。
  • 最常见涉及ADR的药物为来那度胺(30,12.5%)(主要为中性粒细胞减少、血小板减少和双系血细胞减少)、贝伐珠单抗(19,7.9%)(主要为静脉和肺血栓栓塞)和舒尼替尼(13,5.4%)(主要为血栓栓塞事件、腹泻和慢性肾衰竭加重)。
  • 最常见ADR为血细胞减少(40,17.3%)、腹泻(15,6.5%)、乏力(9,3.9%)和神经病变(6,2.6%)。
  • 所有ADR均为严重,10例(6例患者)描述不佳或未知,仅9例(5例患者)通过自发报告上报。

关键数值与推荐

  • 因不可接受毒性停用HOT的登记占比:1.5%(136/全部登记)。
  • 因不可接受毒性停用HOT的患者占比:1.7%(135/全部患者)。
  • ADR/HOT组合数:240对;其中额外监测药物占47%(24种),有EMA RMP占72.5%(37种)。
  • 最常见ADR频率:血细胞减少17.3%(40例)、腹泻6.5%(15例)、乏力3.9%(9例)、神经病变2.6%(6例)。

临床怎么用

  • 临床药师可利用患者与治疗登记处主动识别因严重毒性停用的门诊治疗。
  • 对来那度胺、贝伐珠单抗和舒尼替尼等药物应重点监测血细胞减少和血栓栓塞事件。
  • 登记处数据可补充自发报告,提高严重和未知ADR的发现率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To retrospectively analyse hospital outpatient treatment (HOT) withdrawal due to unacceptable toxicity at our hospital. Information regarding unacceptable toxicity leading to treatment withdrawal was recorded. METHODS: HOT interruptions because of unacceptable toxicity were identified from the Register of Patients and Treatments (RPT) (January 2014 to December 2017). Information regarding the demographic and clinical characteristics of patients, adverse drug reactions (ADRs) and drug treatments was retrieved from electronic health records. Causality and previous knowledge of ADRs were assessed according to the Spanish Pharmacovigilance System algorithm. Information regarding HOT risk management plans (RMPs) and their classification as inverted black triangle medicines was obtained from the European Medicines Agency (EMA). RESULTS: HOTs were withdrawn due to unacceptable toxicity in 136 (1.5%) registries corresponding to 135 (1.7%) patients. Fifty-one different HOTs (38.6% of those registered) were involved in 240 ADR/HOT pairs: 24 (47%) were additional monitoring medicines and 37 (72.5%) were EMA RMPs. The most frequent medicines involved in ADRs were lenalidomide (30, 12.5%) (mainly neutropenia, thrombocytopenia and bicytopenia), bevacizumab (19, 7.9%) (mainly venous and pulmonary thromboembolism) and sunitinib (13, 5.4%) (mainly thromboembolic events, diarrhoea and worsening of chronic renal failure). Cytopenia (40, 17.3%), diarrhoea (15, 6.5%), asthenia (9, 3.9%) and neuropathy (6, 2.6%) were the most frequent ADRs. All ADRs were severe, 10 (6 patients) had been poorly described or were unknown and only 9 (5 patients) had been reported by spontaneous notification. CONCLUSIONS: Valuable information regarding severe and unknown ADRs was obtained from the RPT. Such registers are useful tools to complement spontaneous ADR notifications.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Agustí A, Aguilera C, Bosch M, et al. Withdrawal of hospital outpatient treatments in severe diseases due to unacceptable toxicity: A retrospective study from the register of patients and treatments. Br J Clin Pharmacol. 2020. PMID: 33216993. doi:10.1111/bcp.14665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。